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Cytokeratin 8 (CK8) is one of at least 21 related cytokeratins that
form intermediate filaments in various epithelial cells and carci-
noma cells (Moll et al, 1982). Numerous studies have shown that
high levels of CK8 exist in malignant cells. It has been reported
that CK8 can be expressed at the surface of mammary carcinoma
cells but not in normal mammary epithelial cells (Donald et al,
1991; Godfroid et al, 1991; Hembrough et al, 1995, 1996).
Similarly, it has been shown that all non-small-cell lung cancers
(NSCLC) express CK8 (Blobel et al, 1984; Broers et al, 1988;
Pendleton et al, 1992, 1994).
It has also been reported that the expression of CK8 has been
correlated with increased invasiveness in vitro and in vivo. In
malignant melanoma, in vitro invasiveness has been directly
correlated with cellular expression of intermediate filaments
(Hendrix et al, 1996). In transitional cell carcinoma and squamous
cell carcinoma, CK8 has been detected at increased levels by
immunohistochemistry at the tumour invasion front (Schaafsma et
al, 1991, 1993). In addition, the most tumorigenic clones of SW
613-S cells express the highest levels of CK8 mRNA (Modjtahedi
et al, 1992). Furthermore, mouse L fibroblasts, which lack CK8
and 18, show increased motility and penetration of Matrigel in
vitro after transfection of CK8 DNA (Chu et al, 1993).
CK8 or CK8 fragments have also been detected in conditioned
culture medium (Chan et al, 1986) and in the serum and body
fluids of patients with a variety of cancer types (Bjorklund and
Bjorklund, 1983; Pendleton et al, 1994). One study has demon-
strated the presence of elevated levels of CK8 and degraded frag-
ments of this polypeptide in patients with colonic and pancreatic
tumours (Sundstrom et al, 1990). In addition, Pendleton et al
(1994) have demonstrated that undegraded CK8 is found in the
serum of a subgroup of patients with NSCLC. Furthermore, auto-
antibodies to intermediate filaments have been found in patients
with lung cancer (Hinter et al, 1983).
Under this background, we hypothesized that some antigenic
changes of CK8 may occur in human NSCLC. To prove this, a
Western immunoblot analysis and immunohistochemistry of CK8
was performed in NSCLC cell lines.
MATERIALS AND METHODS
Cell lines (Table 1)
We used cell lines as follows: A549, PC3, PC9, RERF-LC-OK,
LC2/AD (derived from adenocarcinoma of the lung), EBC1,
VMRC-LCD and LC1/SQ (derived from squamous cell carcinoma
of the lung). All cell lines were cultured in RPMI-1640 with 10%
fetal calf serum.
SDS-PAGE electrophoresis and Western blotting
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed according to Laemmli’s method
(Laemmli, 1970) with a slight modification. Whole cell lysates of
cell lines were mixed with SDS (2.0%) and heated (100°C, 5 min).
The samples were then applied to a 10/20% SDS polyacrylamide
gel, electrophoresed (60 mA, 120 min), fixed in 50% methanol,
10% acetic acid and stained with Coomassie Blue. Standard mole-
cular weight markers purchased from Daiichi-Kagaku (Tokyo,
Japan) were comprised of egg lysozyme (MW 14 400), trypsin
inhibitor (MW 20 100), carbonic anhydrase (MW 30 000) aldolase
(MW 42 400) bovine albumin (MW 66 000) and phosphorylase B
from rabbit muscle (MW 97 400). Commercially available puri-
fied recombinant human CK8 (Progen Biotechnik GMBH, lot
503209, Heiderberg, Germany) was also used as the positive
control.
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membrane by the method of Towbin et al (1983). Proteins were
detected by immunoblotting, using five clones of anti-CK8 mono-
clonal antibodies (clones Ks 8.7, Ks 8.10, Ks 8.17.2, and M20
were purchased from Progen Biotechnik GMBH, Heidelberg,
Germany; clone C-51 was purchased from YLEM S. r. 1., Roma,
Italy), peroxidase-conjugated goat anti-mouse IgG antibody
(Sigma ImmunoChemicals, lot 094H-4810, St Louis, MO, USA),
and stained with 4CN PLUS for chromogenic detection of horse-
radish peroxidase (NEMTM Life Science Products, Boston, MA,
USA). Western immunoblots for CA19–9 were also performed
using three clones of anti-CA19–9 monoclonal antibodies (clone
C241:5:1:4 was purchased from YLEM S. r. 1., Roma, Italy; clone
ZY-CO9 was purchased from Zymed Laboratories, Inc., San
Francisco, CA, USA; clone 1116–NS–19–9 was purchased from
Centocor Co., Malvern, PA, USA), and peroxidase-conjugated
goat anti-mouse IgG antibody IgG antibody, and stained with 4CN
PLUS.
Immunohistochemistry of lung cancer cells by several
anti-CK8 antibodies
To evaluate the expression of CK8 in several NSCLC cell lines,
immunohistochemical staining by anti-human monoclonal anti-
body against CK8 was performed. Cells were immunohistochemi-
cally stained, employing the avidin–biotin peroxidase complex
method (Dako LSAB kit-peroxidase, DAKO Corp., Kyoto, Japan)
using mouse monoclonal antibodies against CK8 (clone 35 bH11,
Enzo Diagnostics, Inc., New York, NY, USA, 1:5000 dilution). In
order to retrieve and increase the immunoreactivities, preincuba-
tion with 0.1% pronase at 37°C for 20 min was performed.
Lectin blotting
SDS-PAGE and protein transfer onto nitrocellulose membrane
was performed as described above. Ten kinds of horseradish
peroxidase-labelled lectins, purchased from EY Laboratories, Inc.
(San Mateo, CA, USA), were used for lectin blotting. Proteins
were detected by ten kinds of peroxidase-labelled lectins (1:100
dilutions, following manufacturer’s instruction), and stained with
4CN PLUS. Lectins used were as follows; Maclura pomifera
lectin (MPA), Aracjis hypogaca lectin (PNA), Glycine max lectin
(SBA), Griffonia simplicifolia lectin (GS-II), Griffonia simplici-
folia lectin (GS-I), Ulex europaeus lectin (UAE-I), Triticum
vulgare lectin (WGA), Dolichos biflorus lectin (DBA), Canavalia
ensiformis lectin (Con A) and Bauhinia purpurea lectin (BPA).
RESULTS
Western immunoblot analysis using anti-CK8 antibody (clone Ks
8.7) against lysates of several NSCLC cell lines is shown in Figure
1. Although a molecular weight of 54 kDa, which is the same as
recombinant CK8, was detected in PC3, PC9, LC2/AD and EBC1,
a positive band which had a higher molecular weight was detected
in RERF-LC-OK and LC1/SQ cells. In A549 cell lines, two types
of CK8 were observed.
Western immunoblot analysis using several monoclonal anti-
CK8 antibodies demonstrated that the higher molecular weight
protein was stained by five clones of anti-CK8 antibodies with
varying intensities (Figure 2). Although CK8 with a higher molec-
ular weight was weakly stained by monoclonal antibodies; clones
Ks 8.7, Ks 8.10 and M20, it was strongly stained by monoclonal
anti-CK8 antibodies; clone Ks 8.17.2 and clone C-51.
Western immunoblot analysis using several monoclonal anti-
human CA19–9 antibodies also demonstrated that the higher
molecular weight protein was stained by three clones of anti-
human CA19–9 antibodies (Figure 3). Recombinant CK8 was also
weakly stained by anti-human CA19–9 antibodies.
Immunohistochemical staining of several lung cancer cells with
anti-CK8 monoclonal antibody was restricted to the cytoplasm,
and the cell membranes were completely negative (Figure 4). The
two cell lines containing CK8 with a higher molecular weight
(RERF-LC-OK and LC1/SQ) were not stained by anti-CK8 anti-
body; clone 35bH11. Table 1 summarizes the results of immuno-
histochemical staining of several NSCLC cell lines.
Results of lectin blotting using ten kinds of peroxidase-labelled
lectins are summarized in Table 2. The higher molecular weight
CK8 was stained stronger than usual CK8 by MPA, GS-II, UEA-I,
DBA and BPA lectins.
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Table 1 Lung cancer cell lines evaluated
Cell lines Histology Western Immunohistochemistry
immunoblot
A549 Adenocarcinoma + +
PC3 Adenocarcinoma + +
PC9 Adenocarcinoma + +
RERF-LC-OK Adenocarcinoma +a –b
LC2/AD Adenocarcinoma + +
EBC1 Squamous cell carcinoma + +
VMRC-LCD Squamous cell carcinoma ± +
LC1/SQ Squamous cell carcinoma +a –b
aCytokeratin 8 which had a higher molecular weight. bClone 35bH11 was used as anti-cytokeratin 8 antibody.
12345678
66267
42400
* **
Figure 1 Western immunoblot analysis using anti-cytokeratin 8 monoclonal
antibody (clone Ks 8.7) against lysates of several NSCLC cell lines. Lane 1;
A549, lane 2; PC3, lane 3; PC9, lane 4; RERF-LC-OK, lane 5; LC2/AD, lane
6; EBC1, lane 7; VMRC-LCD, lane 8; LC1/SQ. Although 54 kDa cytokeratin 8
is demonstrated in A549, PC3, PC9, LC2/AD (arrow *), another band which
has a higher molecular weight than usual is demonstrated in RERF-LC-OK
and LC1/SQ (arrow **)DISCUSSION
In our present study, we confirmed the expression of CK8 in all
NSCLC cell lines. In addition, we first demonstrated CK8 with a
higher molecular weight than usual in two of eight NSCLC cell
lines, and it contained antigenic epitopes of CA19–9.
It has been reported that CK8 extends from the nucleus to the
plasma membrane where it has extensive interactions with the
internal leaflet and with various membrane-associated structures,
including desmosomes and hemidesmosomes (Owaribe et al,
1991; Garrod, 1993). Although the sequence of CK8 does not
include a transmembrane domain, it has been proposed that CK8 is
also present on the external surfaces of epithelial cells (Donald et
al, 1991; Godfroid et al, 1991; Hembrough et al, 1995, 1996).
Recently, it has been suggested that CK8 has a function in addi-
tion to as an intermediate filament. Schaafsma et al (1991, 1993)
have suggested that expression of CK8 correlates with increased
invasiveness in vitro and in vivo in many cancers. In addition,
Hembrough et al (1995, 1996) reported that CK8 at the cell surface
of hepatocytes, HepG2 cells and breast carcinoma cell lines func-
tion as a plasminogen receptor. Since plasmin which is activated
by the proteolytic conversion of single-chain plasminogen is
important for tumour invasion and cellular migration, CK8, which
by binding plasminogen, supports or accelerates cellular migration
and invasion (Hembrough et al, 1995, 1996).
This is the first study to report CK8 with a higher than usual
molecular weight in two NSCLC cell lines (RERF-LC-OK and
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Table 2 Summary of results of lectin blotting
Lectins Carbohydrate specificity CK8 Large CK8
MPA N-Acetylgalactosamine ± ++
PNA Terminal-b-Galactose – ±
SBA a and b N-Acetylgalactosamine – –
GS-II N-Acetylglucosamine – ++
GS-I Melibiose, a-D-Galactose – +
UEA-I a-L-Fucose ± ++
WGA (GlcNAc-b-(1,4)-GlcNAc) 1–4 + +
DBA Methyl-2-acetamido-2-deoxy-D-galactose + ++
Con A a-D-Mannose, a-D-Glucose, Branched mannose – –
BPA N-Acetylgalactosamine – ++
123 4 56
66267
42400
* **
123 4 56
66267
42400
* **
123 4 56
* **
66267
42400
* **
66267
42400
123 4 56
123 4 56
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* **
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Figure 2 Western immunoblot analysis using the five clones of anti-human
cytokeratin 8 monoclonal antibodies. (A) clone Ks 8.7, (B) clone Ks 8.10,
(C) clone Ks 8.17.2, (D) clone C-51, (E) clone M20. Lane 1 and 6:
recombinant cytokeratin 8, lane 2: A549, lane 3: PC9, lane 4: RERF-LC-OK,
lane 5: LC1/SQ. Although 54 kDa cytokeratin 8 is demonstrated in A549,
PC3, PC9, LC2/AD (arrow *), another band which has a higher than usual
molecular weight is demonstrated in RERF-LC-OK and LC1/SQ (arrow **).
The intensity of staining for CK8 with a higher than usual molecular weight
differs according to clones of antibodies
Figure 3 Western immunoblot analysis using the three clones of anti-
human CA19-9 monoclonal antibodies. (A) clone C 241:5:1:4, (B) clone
ZY-C09, (C) clone 1116-NS-19-9. Lane 1 and 6: recombinant cytokeratin 8,
lane 2: A549, lane 3: PC9, lane 4: RERF-LC-OK, lane 5: LC1/SQ. Although
54 kDa cytokeratin 8 (arrow **) in NSCLC cell lines is not stained by
anti-CA19-9 monoclonal antibodies, cytokeratin 8 which has a higher than
usual molecular weight (arrow*) is clearly stained by all anti-CA19-9
monoclonal antibodies. Recombinant cytokeratin 8 is also weakly stained by
anti-CA19-9 monoclonal antibodiesLC1/SQ). In addition, although it has been reported that CK8 is
glycosylated at multiple sites with a single O-linked N-acetyl-
glucosamine (Chou et al, 1992), we demonstrate for the first time
that CK8 with a higher than usual molecular weight contained
antigenic epitopes of CA19–9. In addition, using lectin blotting,
we also demonstrated that N-acetylgalactosamine (detected by
MPA lectin), N-acetylglucosamine (detected by GS-II lectin), and
a-L-fucose (detected by UEA-I lectin), these carbohydrates are
constituents of antigenic epitopes of CA19–9, were increased in a
higher molecular weight CK8. Furthermore, this CK8 was only
weakly stained by some clones of anti-CK8 monoclonal anti-
bodies, and cell lines which expressed CK8 with a higher than
usual molecular weight were not stained by anti-CK8 monoclonal
antibody; clone 35bH11, immunohistochemically. Interestingly,
CK8 was stained only in the cytoplasm in lung cancer cell lines
which expressed CK8 with a usual molecular weight. In contrast,
the two cell lines containing CK8 with a higher molecular weight
(RERF-LC-OK and LC1/SQ) were not stained by anti-CK8 anti-
body; clone 35bH11. This evidence suggests that antigenic
changes of CK8 occurred in both of these NSCLC cell lines. These
antigenic changes may explain previous observations of anti-
cytokeratin antibodies in sera of patients with lung cancer (Hinter
et al, 1983).
Although the assay of serum CA19–9 has been widely used for
the diagnosis and monitoring patients with several kinds of cancer,
less is known about the protein(s) on which CA19–9 is expressed.
Koprowski et al (1979) have revealed that monoclonal antibodies
for the CA19–9 antigen precipitates the molecules with molecular
weight of 36 kDa and more than 180 kDa from colon carcinoma
cell extract. On the other hand, the CA19–9 immunoreactivity
detected in the sera of patients (Magnani et al, 1983), normal and
neoplastic mucosa (Fezi et al, 1984), normal seminal plasma
(Hanisch et al, 1984), normal milk (Hanisch et al, 1985) and
pancreatic juice (Kalthoff et al, 1986), has been reported to have a
much higher molecular weight probably due to complex formation
with other components such as mucin-like glycoproteins. In addi-
tion, Klug et al (1988) purified a glycoprotein (an apparent molec-
ular mass of 210 kDa) with the CA19–9 activity from the culture
supernatant of human colonic cell line SW1116 by using an
immunoaffinity chromatography. Furthermore, Haga et al (1989)
have partially purified the CA19–9 antigen from the ascitic fluid
of a pancreatic cancer patient, and determined the molecular
weight to be 210 kDa by Western blotting analysis. These observa-
tions suggest that the CA19–9 epitopes of the cancer cell surface is
not expressed by a single glycoprotein but, rather, by multiple
glycoproteins. In the present study, we first demonstrate the possi-
bility of CK8 as a carrier protein of CA19–9 in some NSCLC cell
lines. The result of lectin blotting clearly demonstrated increases
of carbohydrate epitopes in CK8 with a higher molecular weight.
However, since the recombinant CK8 was also stained by anti-
CA19–9 antibodies, the possibility of cross-reactivity of anti-
carbohydrate antibodies to the specific amino acid sequence in
recombinant CK8 should also be considered.
The biological significance of CA19–9 should be discussed.
Basu et al (1987) reported that a significant portion (20–80%) of
protein-associated CA19–9 of human cancer cell membranes is
intrinsic to a 170 kDa epidermal growth factor (EGF) receptor.
However, Klug et al (1988) reported that the amino acid composi-
tion of the glycoprotein which contains the CA19–9 antigen is
different from that of the EGF receptor. Recent studies also
provide evidence that CA19–9 can serve as a ligand for the
endothelial cell leucocyte adhesion molecule-1 (ELAM-1, also
called E-selectin) (Takada et al, 1991, 1993). ELAM-1 mediates
the cell–cell interaction of platelets and endothelial cells with
neutrophils, monocytes and also cancer cells. Thus, when cancer
cells express CA19–9, they appear to play an important role in the
process of haematogenous metastasis (Takada et al, 1991, 1993).
Several immunohistochemical studies have demonstrated that
expression of CA19–9 is correlated with a high risk of distant
metastasis and poor outcome in lung cancer patients (Sugiyama et
al, 1992, Ogawa et al, 1994). This evidence suggests strongly that
CA19–9 also plays a role in metastatic processes, in vivo.
As stated previously, CK8 has several functions including the
invasion of cancer cells. In addition, CA19–9 plays a role as a
ligand of E-selectin which is closely related to metastasis. This
evidence suggests that CK8 which contained antigenic epitopes of
CA19–9 played an important role in invasion as well as metastasis
of NSCLC cells. The existence of this abnormal CK8 in clinical
samples should be evaluated in future studies. In addition, to
clarify the function of this modified CK8, the differences of CK8
between primary and metastatic tumours should be evaluated in
future studies.
In summary, this is the first report of CK8 with a higher than
usual molecular weight, possibly due to the attachment of anti-
genic epitopes of CA19–9, in two of eight NSCLC cell lines. This
CK8 may have functions in the process of invasion or haemato-
geneous metastasis in NSCLC.
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